Business
Curis Announces Updated Data with Additional Encouraging Clinical Activity in Phase 1/2 Study of CA-4948 Monotherapy in Targeted Patients with Relapsed or Refractory AML and MDS; and Initial Clinical Data from Phase 1 Study of CI-8993 in Patients with...
Curis Announces Updated Data with Additional Encouraging Clinical Activity in Phase 1/2 Study of CA-4948 Monotherapy in Targeted Patients with Relapsed or
About this update from Curis, Inc.
[{"type":"text","content":"Curis Announces Updated Data with Additional Encouraging Clinical Activity in Phase 1/2 Study of CA-4948 Monotherapy in Targeted Patients with Relapsed or Refractory AML and MDS; and Initial Clinical Data from Phase 1 Study of CI-8993 in Patients with Relapsed or Refractory Solid Tumors \n 40% CR/CRh rate (complete remission and complete remission with partial hematologic recovery) in R/R AML patients with U2AF1 or SF3B1 spliceosome mutation treated with CA-4948\n 57% ORR (objective response rate) observed in R/R MDS patients with U2AF1 or SF3B1 spliceosome mutation treated with CA-4948\n Added potential benefit of FLT3 inhibition highlighted by significant marrow blast reduction and eradication of FLT3 mutation in 2 out of 3 R/R AML patients with FLT3 mutation at baseline following treatment with CA-4948\n Promising initial safety data of CI-8993 highlights effectiveness of procedures implemented to manage expected cytokine release syndrome and enable dose escalation past 0.3 mg/kg\n Pharmacodynamic data provide early indication that targeting VISTA with CI-8993 may activate multiple anti-cancer mechanisms\n Management to host conference call today at 8:00 a.m. ET\n\n\nLEXINGTON, Mass., Jan. 6, 2022 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today announced positive updated clinical data from the ongoing open label Phase 1/2 dose escalation and expansion study of CA-4948, a novel, small molecule IRAK-4 inhibitor, as a monotherapy in patients with relapsed or refractory (R/R) acute myeloid leukemia (AML) or high risk myelodysplastic syndromes (MDS) as well as initial safety, pharmacokinetic and pharmacodynamic data from the Phase 1 dose escalation study of CI-8993, a monoclonal antibody targeting VISTA for patients with R/R solid tumors.\n\n \n \n \n \n \n \n\n \n\"These data continue to build on what we believe to be a compelling profile for CA-4948, showing its activity as a monotherapy in a targeted population of patients living with R/R AML/MDS, for whom prior lines of therapy have been unsuccessful,\" said James Dentzer, President and Chief Executive Officer of Curis. \"We are especially pleased that these results demonstrate both a favorable safety profile and improved anti-cancer activity compared with standard of c...